Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

UT Southwestern's support group book shares stories of members whose wives battled cancer

When a loved one has cancer, it affects the entire family. For men, many of whom are less likely to take advantage of a support group, this can leave a void with devastating emotional consequences.

30 Jul 2011

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

30 Jul 2011

Studies reveal new set of mutations linked with head and neck cancer

Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer.

29 Jul 2011

NanoString introduces new assay for leukemia fusion gene analysis

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.

From NanoString Technologies 29 Jul 2011

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris Group today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Puget Sound Blood Center, Seattle Children's inaugurate new on-site lab

Today, Seattle Children's and Puget Sound Blood Center opened a new blood laboratory to serve Children's patients exclusively. Located within Seattle Children's main campus and staffed by Puget Sound Blood Center employees 24 hours every day of the year, the facility will bring the lab closer to the patient.

28 Jul 2011

New series of hospital-based adventure books for children

Hospitals can be scary and overwhelming for kids, and Hospital Critterz, a new series of hospital-based adventure books, helps children see the medical world differently.

27 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

Zinc lozenges might treat natural common cold infections

Depending on the total dosage of zinc and the composition of lozenges, zinc lozenges may shorten the duration of common cold episodes by up to 40%, according to a study published in the Open Respiratory Medicine Journal.

26 Jul 2011

Two genetic variations can identify children at higher risk of radiation-induced second cancers

A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.

25 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

First genome-wide mapping of DNA modification in embryonic stem cells

Stem cell researchers at UCLA have generated the first genome-wide mapping of a DNA modification called 5-hydroxymethylcytosine (5hmC) in embryonic stem cells, and discovered that it is predominantly found in genes that are turned on, or active.

22 Jul 2011

Leading cancer specialists and researchers establish Australia’s first comprehensive ‘Cancer Survivors Centre’

Australia’s first comprehensive treatment and research centre for the growing number of cancer survivors will be announced at the annual Ride for Life luncheon at NSW Parliament House today.

22 Jul 2011

Taller women more prone to cancer: Study

New research has shown that taller women could be more prone to suffering from cancer. The British study published online in the medical journal The Lancet on Thursday said cancer risk rose about 16% for every 4-inch rise in height. Increasing height heightened the chances of cancers of breast, ovary, womb, bowel, leukemia and malignant melanoma (skin cancer) the study found.

21 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011